You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
120-X-2 Unmanned Aircraft System-Borne Atmospheric & Sea Surface Temperature (SST) Sensing
SBC: PIASECKI AIRCRAFT CORP Topic: 84To capture critical weather and SST data in the Tropical Cyclone Boundary Layer (TCBL), Piasecki Aircraft proposes to evaluate existing meteorological sensor packages, integrate new off-the-shelf MEMS sensors, and design an air-launched UAS to improve the resolution of observations captured in the TCBL. Capturing latent and sensible heat fluxes can be achieved reliably with a powered UAS (compare ...
SBIR Phase I 2014 Department of CommerceNational Oceanic and Atmospheric Administration -
Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; however, there is currently no cure for the disease. Discovery that a naturally occurring variant of CCR5, the delta32 mutation, renders cells resistant to HIV infection has led to efforts by several a ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Local Lymph Node Assay with IL-18 Endpoints
SBC: MB RESEARCH LABORATORIES, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The current industry standard for predicting contact dermal sensitization is the murine Local Lymph Node Assay (LLNA). A significant limitation of the LLNA is the frequency of false positives, as well as the occurrenceof false negatives. This limitation occurs as a result of the LLNA inability to always correctly distinguish between substances that are strongly ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Formulation of LbL microparticle vaccine in microneedle array for intradermal del
SBC: ARTIFICIAL CELL TECHNOLOGIES INC Topic: NIAIDAbstract The ability of the immune system to recognize and initiate an immune response to foreign particles such as bacteria and viruses has generated interest in development of particulate vaccine technologies. We are developing an innovative approach toproduce particulate vaccines via layer-by-layer (LbL) fabrication of synthetic microparticles (MP). We have shown that LbL-MP loaded with epitope ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenz
SBC: EVRYS BIO LLC Topic: NIAIDDESCRIPTION (provided by applicant): Despite improvements in vaccine design, manufacture, and distribution, influenza A infection remains a significant public health concern. The February 2013 CDC Interim Adjusted Estimates of Seasonal Influenza Vaccine Effectiveness reported overall vaccine effectiveness of 56% and 67% against influenza A and B infections, respectively, with much reduced effect ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A New Generation of Botulinum Toxin Vaccines
SBC: INVENTOX INC Topic: NIAIDDESCRIPTION (provided by applicant): Botulinum toxin is one of the six categories of pathogens that have been designated as Category A Select Agents by the Centers for Disease Control. The toxin, which is generally acknowledged to be the most potent biological poison known, enters the body and acts on peripheral cholinergic nerve endings to cause paralysis of transmission. In seriously poisoned pa ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Single Antiviral to Treat Multiple Opportunistic Infections
SBC: EVRYS BIO LLC Topic: NIAIDDESCRIPTION (provided by applicant): Transplant patients are quite susceptible to opportunistic viral infection resulting from immune suppression necessary for maintenance of their graft. In the case of renal transplant, 17,604 patients in 2011, a new graft means being taken off dialysis, improving quality of life and saving U.S. healthcare nearly 1 B annually. Therefore it is essential that the ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel bispecific T cell engaging antibodies for treatment of Lyme disease
SBC: ABZYME THERAPEUTICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): Lyme disease (LD) is the most commonly reported tick-borne illness in the United States. According to the recent Center for Disease Control and Prevention report, approximately 300,000 Lyme cases are diagnosed each year. If left untreated, the infection spreads to joints, the heart and the nervous system. In most cases, infections and associated symptoms are el ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
An antimicrobial-eluting bioresorbable bone filler for orthopaedic application
SBC: CarMell Therapeutics Corporation Topic: NIAMSDESCRIPTION (provided by applicant): The long-term goal of Carmell Therapeutics for this proposal is to develop a blood plasma-based biomaterial bone filler product that will elute antimicrobials to inhibit infection. Bacterial contamination is present perioperatively in 48-68% o all open wounds and 100% of severe open injuries. Per year in the U.S. ~ 123,000 open tibia fractures are contaminated, ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Coincident light/ultrasound therapy to treat acne vulgaris and atopic dermatitis
SBC: SONIC TECH, INC. Topic: NIAMSDESCRIPTION (provided by applicant): Sonic Tech Inc. is developing a unique energy-based therapy called CLENS (Coincident Light Energy and Non-focused ultraSound). Using two well-established clinical energy sources in a novel way, the technology is intended to treat dermal diseases caused by biofilms, a bacterially generated slime layer. Biofilms shield bacteria from attack by both antibiotics an ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health